Business Wire

IN-NTT/NTT-DATA

23.5.2024 16:06:30 CEST | Business Wire | Press release

Share
NTT and NTT DATA Roar into the Indianapolis 500 with AI-powered Fan Experience

NTT, a leading global technology and business solutions provider, and NTT DATA continue to expand innovative use of racing data to improve fan experiences across the NTT INDYCAR SERIES, including this year’s Indianapolis 500.

NTT is the parent company of NTT DATA, and they serve together as Official Technology Partner of INDYCAR, the NTT INDYCAR SERIES, Indianapolis Motor Speedway (IMS), the Indianapolis 500, and NASCAR Brickyard weekend.

Through 140-plus sensors on each racecar, NTT DATA captures and analyzes more than 8 billion racing datapoints in the NTT Smart Solutions Platform. Leveraging advanced AI and predictive analytics, the company shares near-real-time insights and visualizations to fans both onsite and remotely for enhanced storytelling of key moments during events including head-to-head overtaking, race strategies, race winner predictions and more. Additionally, the 300,000-plus fans onsite for the race benefit from data on wait times and flow across the 600-plus acre venue calibrated every 30 seconds.

SMART Venues Improve the Fan Experience
Fans at the Indianapolis 500 or other events at the Indianapolis Motor Speedway can experience NTT DATA Smart Venue technology, sustainability solutions and live race data at the Pagoda command displays. For example, AI-enabled optical detection technologies improve security and traffic flow, and when combined with digital ticketing, provide real-time and future prediction wait times at the event gates and concessions. This allows fans at the world’s largest single-day sporting event to move through the venue as safely and efficiently as possible.

AI-enabled Racing Insights
Whether at the racetrack, at home or on the go, fans of the NTT INDYCAR SERIES can also tap into the INDYCAR App Powered by NTT DATA to stay up to date on all of the latest developments. The App allows fans to get even closer to the action with real-time, AI and advanced analytics providing racing insights that include live scoring and viewing of the drivers in action courtesy of 15 in-car cameras. The App, which historically engages more than 70,000 users on race days, is available for download from the iOS App Store and Google Play.
NTT DATA also continues to enable other similar innovative experiences to benefit fans and increase engagement across all mediums, via social media, the web and television or streaming broadcast, through reliable technology and services that deliver deeper data insights.

Race Like the Pros
This year, a new limited racing demonstration will leverage Embodied Knowledge technology from NTT R&D. Embodied Knowledge powers simulators that blend physical sensations with digital innovation, allowing users to precisely experience a track as driven by a professional driver. Beyond the experience of traditional simulators, Embodied Knowledge adds the actual feel and performance of the professional driver at high speeds at the Indianapolis Motor Speedway including realistic steering wheel forces and car behavior like vibrations and forces exerted on seat, users can synchronize their movements with that of a professional driver via XR.

NTT Embodied Knowledge technology is being explored for future use cases including medical surgery training, coaching and fan experiences in sports. Future applications include employee training across retail, education, and manufacturing, as well as enabling AI-robots to learn how to move and react the way humans do to perform tasks from restocking shelves to in-home caregiving. The effort is part of the more than $3.6B NTT invests each year in research and development, uncovering innovations that have commercial impact for their customers.

“The Indianapolis 500 is the pinnacle of racing that leverages refined Embodied Knowledge where firsthand the movements of racers can be felt to understand what Embodied Knowledge truly means. Through various sensing technologies, we aim to technically recreate these movements and sensations.” said Kota Hidaka, Vice President, Head of NTT Human Informatics Laboratories.

To learn more about the NTT INDYCAR SERIES, visit: https://us.nttdata.com/en/about-us/content/ntt-indycar-series.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523988191/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye